Brand Name :
Seconal
Synonyms :
secobarbital
Class :
Sedative/Hypnotics and Barbiturates
Dosage Forms & Strengths
Capsule
100mg
Indicated for Pre-procedure Sedation :
200 - 300
mg
orally
Prior to surgery
Dose Adjustments
Renal Impairment
lower dose recommended
Hepatic Impairment
lower dose recommended
Dosage Forms & Strengths
Capsule
100mg
Refer to adult dosing
lemborexant may enhance the CNS depressant effect of CNS depressants
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may increase the CNS depressant effect of CNS Depressants
may have an increased CNS depressant effect when combined with buprenorphine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with methotrimeprazine
may have an increased CNS depressive effect when combined with oxycodone
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressant effect when combined with CNS depressants
calcium, magnesium, potassium and sodium oxybate
may have an increased CNS depressant effect when combined with oxybate salt products
suvorexant: they may increase the CNS depressant effect of CNS Depressants
Ropeginterferon Alfa-2b: they may increase the adverse effect of CNS Depressants
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
when both drugs are combined, there may be a decreased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may increase the CNS depressant effect
may increase the CNS depressant effect
CNS depressants increase the effect of CNS depression of thalidomide
CNS depressants increase the efficacy of cannabinoid products
CNS depressants increase the efficacy of cannabinoid products
may increase the CNS depressant effect of bromperidol
may have an increased CNS depressive effect when combined with flunarizine
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with orphenadrine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with paraldehyde
may increase the CNS depressant effect of flibanserin
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may have an increased CNS depressive effect when combined with cannabinoid-containing products
It may enhance sedation when combined with a shepherd's purse
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of sedation of ropinirole
may increase the CNS depressant effect
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may have an increased CNS depressive effect when combined with brexanolone
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with Cyproheptadine
may increase the toxic effect of CNS depressants
may increase the adverse effect of CNS Depressants
doxylamine: they may increase the CNS depressant effect of CNS Depressants
perampanel: they may increase the CNS depressant effect of CNS Depressants
valerian: they may increase the CNS depressant effect of CNS Depressants
it increases the effect of CNS depressants
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect of Doxylamine
metoclopramide increases the effect of CNS depressants
may increase the effects by pharmacodynamic synergism
pramipexole: they may increase the sedative effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
they increase the metabolism of norepinephrine reuptake inhibitors
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
it increases the toxicity of CNS depressants
CNS depressants increase the effect of zolpidem
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
Actions and Spectrum:
Actions:
Spectrum:
Frequency Not Defined
Ataxia
Dizziness
Constipation
Headache
Anxiety
Irritability
Hallucinations
Somnolence
Nightmares
Bleeding
Rash
Fever
Black Box Warning
Black box warning for secobarbital due to the risk of dependence, addiction, and overdose. The warning states that secobarbital should only be used for a short period of time (no longer than two to four weeks) and at the lowest effective dose.
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy warnings:
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is known
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
secobarbital, a barbiturate, is a sedative and hypnotic drug.
It functions by enhancing GABA (gamma-aminobutyric acid) neurotransmitter activity in the brain. GABA controls nerve cell activity, which promotes calm and lowers anxiety. Pharmacodynamics:
When secobarbital is taken, it binds to specific receptors in the brain called GABA-A receptors. This binding causes a conformational change in the receptor, which leads to an influx of chloride ions into the neuron. This influx of ions makes the neuron more negatively charged and less likely to fire, leading to a decrease in neuronal activity and a decrease in overall brain activity.
Pharmacokinetics:
Absorption
It is rapidly absorbed from the gastrointestinal tract after oral administration. The peak plasma concentrations are reached within 1-2 hours
Distribution
It is widely distributed in the body, with a large volume of distribution. It is highly protein-bound, with an estimated binding of 96-98%
Metabolism
secobarbital is metabolized in the liver by hydroxylation and conjugation. The major metabolite is 5-ethyl-5-(1-methylbutyl) barbituric acid
Elimination and excretion
secobarbital is eliminated primarily by renal excretion, with a half-life of approximately 12-16 hours
Administration:
Oral Administration
secobarbital is a barbiturate medication that is used as a sedative and hypnotic. It is administered orally, typically in capsule or tablet form. The dosage and frequency of administration will vary depending on the individual and the condition being treated.
Before administering secobarbital, it is important to assess the patient’s medical history and current medications to ensure that there are no contraindications or potential interactions. The patient should also be monitored for any adverse reactions or side effects, such as drowsiness, confusion, or respiratory depression.
Patient information leaflet
Generic Name: secobarbital
Why do we use secobarbital?
secobarbital is used as a sedative and hypnotic to help individuals with insomnia, anxiety or tension. It works by slowing down the activity in the brain, which promotes relaxation and sleep. It is also used as a preoperative medication to help individuals relax and reduce anxiety before a surgical procedure. It can also be used to treat seizures, severe headaches and chronic pain.